Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash from Financing Activities (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Cash from Financing Activities for 3 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 1230.85% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $129.6 million through Dec 2025, up 647.54% year-over-year, with the annual reading at $129.6 million for FY2025, 647.54% up from the prior year.
  • Cash from Financing Activities hit $1.1 million in Q4 2025 for Compass Therapeutics, down from $129.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $129.4 million in Q3 2025 to a low of -$815000.0 in Q1 2025.
  • Historically, Cash from Financing Activities has averaged $13.6 million across 3 years, with a median of $21000.0 in 2023.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 109.52% in 2024 and later soared 6468150.0% in 2025.
  • Year by year, Cash from Financing Activities stood at -$158000.0 in 2023, then skyrocketed by 40.51% to -$94000.0 in 2024, then surged by 1230.85% to $1.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for CMPX at $1.1 million in Q4 2025, $129.4 million in Q3 2025, and -$815000.0 in Q1 2025.